Synaptogenix responds to fda approval of aducanumab

New york, june 7, 2021 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today issued a statement following the announced fda approval of biogen's new alzheimer's treatment aducanumab. daniel alkon, m.d.
SNPX Ratings Summary
SNPX Quant Ranking